NVAX
NOVAVAX INC
NASDAQ · Healthcare · Biotechnology · US
$10.82
−3.91%Year over year
Reported trailing growth
- Revenue
- -61.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +93.2%
- Operating cash flow
- +93.7%
Forward estimates
Based on analyst estimates
- Revenue
- -4.3%
- EBITDA
- +109.2%
- EPS
- +90.5%
Three-year CAGR
- Revenue
- -11.1%
- EBITDA
- +555.7%
- EBIT
- +326.3%
- Net income
- +334.8%
- EPS
- +321.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026